Month: March 2020

VANCOUVER, British Columbia, March 27, 2020 (GLOBE NEWSWIRE) — TELUS today announced a $500,000 donation to the Vancouver Prostate Centre (VPC), Vancouver General Hospital (VGH) and University of British Columbia (UBC) Hospital Foundation to assist in the search for therapeutic antiviral treatments for COVID-19. Led by Professor Art Cherkasov, VPC and UBC scientists have joined forces with experts around the world including collaborations with Cambridge in the UK, Memorial Sloan-Kettering in New York, University of North Carolina Pharma Science, and Enamine, the biggest small molecule supplier in the world, in the Ukraine. This Vancouver-led team brings together some of the best talent in the world in medicinal chemistry and virology.‘‘We are encouraged by the incredible expertise of the researchers that make up this global consortium...

VANCOUVER, Colombie-Britannique, 27 mars 2020 (GLOBE NEWSWIRE) — TELUS a annoncé aujourd’hui qu’elle fera un don de 500 000 $ au Vancouver Prostate Centre (VPC) et à la fondation de l’hôpital général de Vancouver (VGH) et de l’hôpital de l’Université de la Colombie-Britannique (UBC) pour contribuer à financer la recherche de traitements antiviraux contre la COVID-19. Sous la direction du professeur Art Cherkasov, les scientifiques du VPH, VGH et UBC ont joint les rangs d’experts du monde entier. Ils collaborent notamment avec l’Université de Cambridge au Royaume-Uni, le Memorial Sloan-Kettering à New York, le programme de sciences pharmaceutiques de l’Université de Caroline du Nord, et Enamine, le plus grand fournisseur de petites molécules au monde, en Ukraine. Cette équipe, qui est dirigée à partir de Vancouver, rassemble certains...

Vilnius, March 27, 2020 (GLOBE NEWSWIRE) — Medicinos Bankas UAB would like to inform you that the meeting of the Supervisory Board of the bank of 26 March 2020 elected the current members of the Board, i.e. Dalia Klišauskienė, Igor Kovalčuk and Marius Arlauskas, for a new term of four years. Aleksėjus Tonkich who has been working for the bank since September 2008 and is currently the Director of the Accounting and Reporting Department was elected to be the fourth member of the Board. He will take up his duties as a member of the Board as soon as the Bank of Lithuania gives him permission to act as a manager of the bank.The Supervisory Board of the bank elected the members of the Board at the end of the term provided for in the Statute of the bank.For more information please call : +370 610 21691 or via e-mail: media@medbank.lt ;

Vilnius, March 27, 2020 (GLOBE NEWSWIRE) — UAB Medicinos bankas informuoja, kad 2020 m. kovo 26 d. įvykusio banko stebėtojų tarybos posėdyje naujai ketverių metų kadencijai į banko valdybą išrinkti esami banko valdybos nariai Dalia Klišauskienė, Igor Kovalčuk ir Marius Arlauskas. Ketvirtuoju  valdybos nariu yra išrinktas Aleksėjus Tonkich kuris banke dirba nuo 2008 m. rugsėjo ir šiuo metu eina banko apskaitos ir ataskaitų departamento direktoriaus pareigas. Aleksejus Tonkich pradės eiti valdybos nario pareigas kai bus gautas Lietuvos banko leidimas tapti banko vadovu.Banko stebėtojų taryba valdybą išrinko pasibaigus banko įstatuose nustatytai ketverių metų valdybos kadencijai.For more information please call : +370 610 21691 or via e-mail: media@medbank.lt ;

Copenhagen, March 27, 2020 (GLOBE NEWSWIRE) —Bestyrelsen har i dag behandlet og vedtaget årsrapporten for Investeringsforeningen BankInvestÅrsrapport med beretning, regnskab og nøgletal for den enkelte forening er vedlagt og vil ligeledes kunne rekvireres hos investeringsforvaltningsselskabet/forvalteren BI Management A/S eller downloades via foreningernes hjemmeside www.bankinvest.dk.Årsrapporten vil blive fremlagt til godkendelse på foreningens ordinære generalforsamling.Spørgsmål til årsrapporterne kan rettes til investeringsforvaltningsselskabets/forvalterens vicedirektør Henrik Granlund på tlf. nr. 77 30 90 00.Med venlig hilsenInvesteringsforeningen BankInvestOle Jørgensen                     Ingelise Bogason                Niels HeeringBestyrelsesformand              Næstformand                     NæstformandVedhæftet filÅrsrapport...

STOCKHOLM, SWEDEN – 27 March 2020. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that the company has made an investment in Svenska Vaccinfabriken Produktion AB (“SVF”). SVF develops therapeutic proteins and DNA vaccines against hepatitis B, hepatitis D and other viral diseases, as well as vaccines to prevent infections of Covid-19 and potential future Coronaviruses. SVF’s innovative vaccine platform technology has been developed by researchers at the Karolinska Institute in Huddinge, Sweden. The projects are currently in the preclinical phase and the first clinical trials could potentially be initiated in 2021.As a result of the initial investment, Karolinska Development will own five percent of the shares in SVF. Further, an option agreement gives the opportunity to increase the ownership to a total of...

Due to the development in connection with the outbreak of Covid-19, Solar A/S withdraws the previously announced outlook for 2020.January, February and the first three weeks of March went exactly as planned financially. We are, however, starting to see a slight decline in revenue in some markets.We will disclose a new guidance as soon as we get an overview of the effect the outbreak will have on Solar.Our number one priority is to protect employees and business partners. Thus, we have introduced a number of initiatives to limit the risk of infection in order to ensure our business’ continuity and stability.We are currently only experiencing minor changes in deliveries from suppliers. Our strong partnerships with the suppliers mean that we have alternatives to both products and production sites, and we are doing everything we can to uphold...

På baggrund af udviklingen i forbindelse med udbruddet af Covid-19 trækker Solar A/S nu de tidligere udmeldte forventninger til 2020 tilbage.Januar, februar og de tre første uger af marts er forløbet helt som forventet rent økonomisk. Vi begynder dog at opleve svagt faldende omsætning på enkelte markeder.Vi kommer med en ny guidance, så snart vi har overblik over, hvilken effekt udbruddet vil få for Solar.Vores førsteprioritet er beskyttelse af medarbejdere og samarbejdspartnere. Vi har derfor indført en lang række smittebegrænsende tiltag samt taget initiativer for at sikre kontinuitet og stabilitet i vores forretning.Vi oplever på nuværende tidspunkt kun små ændringer i leverancer fra leverandører. Vores stærke samarbejde med leverandørerne betyder, at vi har alternativer både på produkter og produktionssteder, og vi gør alt, hvad vi...

ELMSFORD, N.Y., March 27, 2020 (GLOBE NEWSWIRE) — NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device which attaches to an indwelling catheter and has been clinically proven to mitigate Catheter Associated Urinary Tract Infection (CAUTI), as well as reducing pain and blockages, today announced that it has reached out to regulatory agencies around the world to inform them of the potential benefits for greater use of the product on compromised patients.  As a result of the COVID-19 crisis, critically ill patients are at the greatest risk, especially when compromised by comorbidities, such as CAUTI.  Additionally, with the existing and potential burden this crisis has on the worldwide healthcare system, critical patients may be...